Pharmacogenetics in future medical care - Implications for patients and physicians;Pharmakogenetische tests in der zukünftigen medizinischen versorgung: Implikationen für patienten und ärzte

Gesundheitswesen

Volumn 67, Issue 4, 2005, Pages 257-263

  Rogausch, Anja ^a   Brockmoller J ^a   Himmel, W ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Ethics; Family practice; Genetic counselling; Informed consent; Pharmacogenetics; Physician patient relations

Indexed keywords

ATTITUDE; DOCTOR PATIENT RELATION; ETHICS; FUTUROLOGY; GENERAL PRACTICE; GENETIC ANALYSIS; GENETIC COUNSELING; INFORMED CONSENT; MEDICAL CARE; PHARMACOGENETICS; REVIEW; RISK BENEFIT ANALYSIS; SOCIOECONOMICS;

FAMILY PRACTICE; FORECASTING; GENETIC COUNSELING; HUMANS; INFORMED CONSENT; PHARMACOGENETICS; PHYSICIAN-PATIENT RELATIONS;

EID: 18944397759     PISSN: 09413790     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-813918     Document Type: Review

References (96)

1. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-549
2. Srivastava P. Drug metabolism and individualized medicine. Curr Drug Metab 2003; 4: 33-44
3. Schaeffeler E, Fischer C, Brockmeier D et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004; 14: 407-417
4. Kaskas BA, Louis E, Hindorf U et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 2003; 52: 140-142
5. Shipkova M, Ahsen Nvon. Therapie mit Thiopurin-Medikamenten - TDM und Pharmakogenomik der TPMT. J Lab Med 2003; 27: 211-221
6. Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos 2001; 29: 601-605
7. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348: 529-537
8. West WL, Knight EM, Pradhan S et al. Interpatient variability: genetic predisposition and other genetic factors. J Clin Pharmacol 1997; 37: 635-648
9. Foster MW, Sharp RR, Mulvihill JJ. Pharmacogenetics, race, and ethnicity: social identities and individualized medical care. Ther Drug Monit 2001; 23: 232-238
10. Evans WE. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit 2004; 26: 186-191
11. Aken Jvan, Schmedders M, Feuerstein G et al. Prospects and limits of pharmacogenetics: the thiopurine methyl transferase (TPMT) experience. Am J Pharmacogenomics 2003; 3: 149-155
12. Williams-Jones B, Corrigan OP. Rhetoric and hype: where's the 'ethics' in pharmacogenomics? Am J Pharmacogenomics 2003; 3: 375-383
13. Nebert DW, Jorge-Nebert L, Vesell ES. Pharmacogenomics and "individualized drug therapy": high expectations and disappointing achievements. Am J Pharmacogenomics 2003; 3: 361-370
14. Goldstein DB. Pharmacogenetics in the laboratory and the clinic. N Engl J Med 2003; 348: 553-556
15. Emery J, Hayflick S. The challenge of integrating genetic medicine into primary care. BMJ 2001; 322: 1027-1030
16. Vaszar LT, Rosen GD, Raffin TA. Pharmacogenomics and the challenge to privacy. Pharmacogenomics J 2002; 2: 144-147
17. Moldrup C. Ethical, social and legal implications of pharmacogenomics: a critical review. Community Genet 2002; 4: 204-214
18. Fears R, Roberts D, Poste G. Rational or rationed medicine? The promise of genetics for improved clinical practice. BMJ 2000; 1; 320: 933-935
19. Lichter JB, Kurth JH. The impact of pharmacogenetics on the future of healthcare. Curr Opin Biotechnol 1997; 8: 692-695
20. Shah J. Criteria influencing the clinical uptake of pharmacogenomic strategies. BMJ 2004; 328: 1482-1486
21. Tucker G. Pharmacogenetics - expectations and reality. BMJ 2004; 329: 4-6
22. Melzer D, Detmer D, Zimmern R. Pharmacogenetics and public policy: expert views in Europe and North America. Pharmacogenomics 2003; 4: 689-691
23. Wertz DC. Ethical, social and legal issues in pharmacogenomics. Pharmacogenomics J 2003; 3: 194-196
24. Melzer D, Zimmern R. Genetics and medicalisation. BMJ 2002; 324: 863-864
25. Becquemont L. Clinical relevance of pharmacogenetics. Drug Metab Rev 2003; 35: 277-285
26. Freund CL, Wilfond BS. Emerging ethical issues in pharmacogenomics: from research to clinical practice. Am J Pharmacogenomics 2002; 2: 273-281
27. Knottnerus JA, Weel Cvan, Muris JW. Evaluation of diagnostic procedures. BMJ 2002; 324: 477-480
28. Robertson JA, Brody B, Buchanan A et al. Pharmacogenetic challenges for the health care system. Health Affairs 2002; 21: 155-167
29. Kumar S, Gantley M. Tensions between policy makers and general practitioners in implementing new genetics: grounded theory interview study. BMJ 1999; 319: 1410-1413
30. Robins R, Metcalfe S. Integrating genetics as practices of primary care. Soc Sci Med 2004; 59: 223-233
31. Marshall E. Preventing toxicity with a gene test. Science 2003; 302: 588-590
32. Mountcastle-Shah E, Holtzman NA. Primary care physicians' perceptions of barriers to genetic testing and their willingness to participate in research. Am J Med Genet 2000; 94: 409-416
33. Kirchheiner J, Nickchen K, Bauer M et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9: 442-473
34. Wolf CR, Smith G, Smith RL. Science, medicine, and the future: Pharmacogenetics. BMJ 2000; 320: 987-990
35. Weihrauch TR. Pharmakogenetik - Auswirkungen auf die Gesundheitsversorgung und die Gesundheitsökonomie. Med Klin 2002; 97: 420-428
36. Kirchheiner J, Meisel C, Goldammer M et al. Pharmakogenetik als Basis neuer Therapiekonzepte. Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz 2003; 46: 835-844
37. Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000; 405: 857-865
38. Ginsburg GS, McCarthy JJ. Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol 2001; 19: 491-496
39. Lash LH, Hines RN, Gonzalez FJ et al. Genetics and susceptibility to toxic chemicals: Do you (or should you) know your genetic profile? J Pharmacol Exp Ther 2003; 305: 403-409
40. Brazell C, Freeman A, Mosteller M. Maximizing the value of medicines by including pharmacogenetic research in drug development and surveillance. Br J Clin Pharmacol 2002; 53: 224-231
41. Lipton P. Pharmacogenetics: the ethical issues. Pharmacogenomics J 2003; 3: 14-16
42. Rothstein MA, Epps PG. Pharmacogenomics and the (ir)relevance of race. Pharmacogenomics J 2001; 1: 104-108
43. Feuerstein G, Kollek R, Schmedders M et al. Irreführende Leitbilder - Zum Mythos der Individualisierung durch pharmakogenetische Behandlungskonzepte. Eine kritische Anmerkung. Ethik Med 2003; 15: 77-86
44. Lee SS. Race, distributive justice and the promise of pharmacogenomics: ethical considerations. Am J Pharmacogenomics 2003; 3: 385-392
45. Schmedders M, Aken Jvan, Feuerstein G et al. Individualized pharmacogenetic therapy: a critical analysis. Community Genet 2003; 6: 114-119
46. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487-491
47. Buchanan A, Califano A, Kahn J et al. Pharmacogenetics: ethical issues and policy options. Kennedy Inst Ethics J 2002; 12: 1-15
48. Meisel C, Roots I, Cascorbi I et al. How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport. Clin Chem Lab Med 2000; 38: 869-876
49. Johnson JA, Lima JJ. Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges. Pharmacogenetics 2003; 13: 525-534
50. Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 2001; 250: 186-200
51. Poirier J, Delisle MC, Quirion R et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A 1995; 92: 12260-12264
52. Emilien G, Ponchon M, Caldas C et al. Impact of genomics on drug discovery and clinical medicine. QJM 2000; 93: 391-423
53. Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001; 2: 9-39
54. Thomas SM. Pharmacogenetics: the ethical context. Pharmacogenomics J 2001; 1: 239-242
55. Renegar G, Rieser P, Manasco P. Pharmacogenetics: the Rx perspective. Expert Rev Mol Diagn 2001; 1: 255-263
56. Issa AM. Ethical perspectives on pharmacogenomic profiling in the drug development process. Nat Rev Drug Discov 2002; 1: 300-308
57. Robertson JA. Consent and privacy in pharmacogenetic testing. Nat Genet 2001; 28: 207-209
58. Broadstock M, Michie S, Marteau T. Psychological consequences of predictive genetic testing: a systematic review. Eur J Hum Genet 2000; 8: 731-738
59. Di Blasi Z, Harkness E, Ernst E et al. Influence of context effects on health outcomes: a systematic review. Lancet 2001; 357: 757-762
60. Hapgood R. The potential and limitations of personalised medicine in primary care. Br J Gen Pract 2003; 53: 915-916
61. Stamp MJ, David SP. Are family physicians willing to use pharmacogenetics for smoking cessation therapy? Fam Med 2003; 35: 83
62. Hoffrage U, Lindsey S, Hertwig R et al. Communicating statistical information. Science 2000; 290: 2261-2262
63. Emery J, Kumar S, Smith H. Patient understanding of genetic principles and their expectations of genetic services within the NHS: a qualitative study. Community Genet 1998; 1: 78-83
64. Emery J. Is informed choice in genetic testing a different breed of informed decision-making? A discussion paper. Health Expect 2001; 4: 81-86
65. Holtzman NA. Putting the search for genes in perspective. Int J Health Serv 2001; 31: 445-461
66. Austin MA, Peyser PA, Khoury MJ. The interface of genetics and public health: research and educational challenges. Annu Rev Public Health 2000; 21: 81-99
67. Gurwitz D, Weizman A, Rehavi M. Education: Teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine. Trends Pharmacol Sci 2003; 24: 122-125
68. Issa AM. Ethical considerations in clinical pharmacogenomics research. Trends Pharmacol Sci 2000; 21: 247-249
69. March R, Cheeseman K, Doherty M. Pharmacogenetics - legal, ethical and regulatory considerations. Pharmacogenomics 2001; 2: 317-327
70. Nebert DW, Bingham E. Pharmacogenomics: out of the lab and into the community. Trends Biotechnol 2001; 19: 519-523
71. McGleenan T, Wiesing U. Versicherung und Genetik - Optionen zur Verhinderung unerwünschter Auswirkungen. Gesundheitswesen 2001; 63: 583-590
72. Feuerstein G, Kollek R, Uhlemann T. Gentechnik und Krankenversicherung. Neue Leistungsangebote im Gesundheitssystem. Baden-Baden: Nomos, 2002
73. Alcalde MG, Rothstein MA. Pharmacogenomics: ethical concerns for research and pharmacy practice. Am J Health Syst Pharm 2002; 59: 2239-2240
74. Weijer C, Miller PB. Protecting communities in pharmacogenetic and pharmacogenomic research. Pharmacogenomics J 2004; 4 (1): 9-16
75. Meyer T, Vinkemeier U, Meyer U. Ethische Folgeeinschätzung von genotyp-basierten Arzneimitteltherapien. Dtsch Med Wochenschr 2002; 127: 2524-2526
76. Post SG, Whitehouse PJ, Binstock RH et al. The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. JAMA 1997; 277: 832-836
77. Lindpaintner K. Pharmacogenetics and the future of medical practice. Br J Clin Pharmacol 2002; 54: 221-230
78. Collins FS, Green ED, Guttmacher AE et al. A vision for the future of genomics research. Nature 2003; 422: 835-847
79. Paul NW, Roses AD. Pharmacogenetics and pharmacogenomics: recent development, their clinical relevance and some ethical, social and legal implications. J Mol Med 2003; 81: 135-140
80. Austin MA. Ethical issues in human genome epidemiology: a case study based on the Japanese American Family Study in Seattle, Washington. Am J Epidemiol 2002; 155: 585-592
81. Rothenberg KH, Terry SF. Human genetics. Before it's too late - addressing fear of genetic information. Science 2002; 297: 196-197
82. Rothstein MA, Epps PG. Ethical and legal implications of pharmacogenomics. Nat Rev Genet 2001; 2: 228-231
83. Winkelmann BR. Pharmacogenomics, genetic testing and ethnic variability: tackling the ethical questions. Pharmacogenomics 2003; 4: 531-535
84. Rothstein MA, Hornung CA. Public attitudes about pharmacogenomics. In: Rothstein MA (Hrsg). Pharmacogenomics: Social, ethical, and clinical Dimensions. New Jersey: John Wiley, 2003: 3-27
85. Jones JK. Pharmacogenetics and pharmacoepidemiology. Pharmacoepidemiol Drug Saf 2001; 10: 457-461
86. Anderson DC, Gomez-Mancilla B, Spear BB et al. Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working group. Pharmacogenomics J 2002; 2: 284-292
87. National Bioethics Advisory Commission (NBAC). Ethical and Policy Issues in Research Involving Human Participants (Bethesda, Maryland: NBAC 2001). http://www.georgetown.edu/research/nrcbl/nbac/pubs.html
88. Human Genetics Commission. Whose hands on your genes? A discussion document on the storage, protection and use of genetic information. London: Human Genetics Commission, 2000 (http://www.hgc.gov.uk/ business_consultations2maintext.pdf)
89. Temporary Committee on Human Genetics and Other New Technologies of Modern Medicine. Erice declaration of the ethical principles of pharmacogenetic research. Temporary Committee on Human Genetics and Other New Technologies of Modern Medicine. Law Hum Genome Rev 2002; 17: 223-228
90. Brand A. Prädiktive Gentests - Pradigmenwechsel für Prävention und Gesundheitsforschung? Gesundheitswesen 2002; 64: 224-229
91. Jallinoja P, Hakonen A, Aro AR et al. Attitudes towards genetic testing: analysis of contradictions. Soc Sci Med 1998; 46 (10): 1367-1374
92. Berth H, Dinkel A, Balck F. Gesundheit durch Gentests? Akzeptanz und Befürchtungen gegenüber genetischen Untersuchungen in einer deutschlandrepräsentativen Stichprobe. Z Gesundheitspsychol 2002; 10: 97-107
93. Berth H, Balck F, Dinkel A. Attitudes toward genetic testing in patients at risk for HNPCC/FAP and the German population. Genet Test 2002; 6: 273-280
94. Lipton P. Nuffield Council on Bioethics consultation. Pharmacogenomics 2003; 4: 91-95
95. Nuffield Council on Bioethics. Pharmacogenetics - ethical issues. Dorchester: The Dorset Press, 2003
96. Paul N, Labisch A. "Health is a crossroad" - Natur und Gesellschaft, Individuum und Gemeinschaft in der öffentlichen Gesundheitssicherung. Gesundheitswesen 2002; 64: 614-622